Connection

Daniel Judge to Lamin Type A

Back to Details
This is a "connection" page, showing publications Daniel Judge has written about Lamin Type A.
Daniel Judge
Connection Strength
0.575
Lamin Type A
  1. Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study. Circ Genom Precis Med. 2023 02; 16(1):e003730.
    View in: PubMed
    Score: 0.210
  2. Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C-Related Dilated Cardiomyopathy. Am J Cardiol. 2022 11 15; 183:93-98.
    View in: PubMed
    Score: 0.207
  3. LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset. Am J Med Genet A. 2013 Jul; 161A(7):1599-611.
    View in: PubMed
    Score: 0.108
  4. The response to cardiac resynchronization therapy in LMNA cardiomyopathy. Eur J Heart Fail. 2022 04; 24(4):685-693.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.